Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. AMD

Go back to Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results

Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval

March 14, 2016 8:01 AM EDT

Needham & Company reiterated a Buy rating and $11.00 price target on Progenics Pharmaceuticals (NASDAQ: PGNX). Needham is anticipating approval of oral Relistor on its April 19th PDUFA date, which will trigger a $50 million milestone payment from Valeant and should lead to a significant increase in Relistor... More

Progenics Pharma (PGNX) Tops Q4 EPS by 4c

March 11, 2016 8:02 AM EST

Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

... More